Drug-Eluting Stents in the Superficial Femoral Artery: The Long and Winding Road.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study.Vascular specialist international · 2019
   Article
2. The role of precise imaging with intravascular ultrasound in coronary and peripheral interventions.Vascular health and risk management · 2019
   Review
3. Inhibitory effect of sustained perivascular delivery of paclitaxel on neointimal hyperplasia in the jugular vein after open cutdown central venous catheter placement in rats.Annals of surgical treatment and research · 2017
   Article
4. State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?Journal of the Society for Cardiovascular Angiography & Interventions
   Article

Corrections and comments

• Comment on
  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as